Abstract
The Philadelphia (Ph) chromosome, a short chromosome 22, is the most frequent cytogenetic abnormality in adult patients with acute lymphoblastic leukemia (ALL). It occurs in approximately 20% to 30% of adults and in about 5% of children with this disease. The incidence rises with age and occurs in approximately 50% of patients older than 50 years. This article reviews the treatment regimens for Ph+ ALL, including imatinib and second generation tyrosine kinase inhibitors (TKIs). The introduction of effective TKIs in the treatment of Ph+ ALL has introduced several avenues of research in a disease that was hitherto difficult to treat.
Original language | English (US) |
---|---|
Pages (from-to) | 1043-1063 |
Number of pages | 21 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 23 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2009 |
Keywords
- Acute lymphoblastic leukemia
- Allogeneic stem cell transplant
- BCR-ABL
- Philadelphia chromosome
- Tyrosine kinase inhibition
ASJC Scopus subject areas
- Hematology
- Oncology